Background and objective: Studies analysing the effect of worsening pulmonary physiological impairment in idiopathic pulmonary fibrosis (IPF) with respect to quality of life have been limited to single centres or highly selected trial populations. The aim of this study was to determine the principal determinants of baseline and longitudinal health-related quality of life (HRQoL) in a large unselected IPF population. Methods: We used the Australian IPF Registry to examine the relationship between HRQoL, measured using the St George Respiratory Questionnaire (SGRQ), and demographic features, physiological features, comorbidities and symptoms. Linear regression analysis was performed to identify predictors of baseline HRQoL, linear mixed model analysis to determine the effect of time and forced vital capacity (FVC) on SGRQ and Cox proportional hazards regression to examine the relationship between HRQoL and all-cause mortality. Results: Baseline data from 516 patients were available (347 males; mean (SD) age: 71.3 AE 8.6 years). Univariate analysis showed significant associations between HRQoL and demographic, clinical and physiological features. However, multivariate analysis demonstrated independent associations only between SGRQ and dyspnoea (University of California San Diego Shortness of Breathlessness Questionnaire (UCSD-SOBQ); R 2 = 0.71, P < 0.0001), cough severity (visual analogue scale; R 2 = 0.06, P < 0.0001) and depression (Hospital Anxiety and
ABSTRACT
Background and objective: Studies analysing the effect of worsening pulmonary physiological impairment in idiopathic pulmonary fibrosis (IPF) with respect to quality of life have been limited to single centres or highly selected trial populations. The aim of this study was to determine the principal determinants of baseline and longitudinal health-related quality of life (HRQoL) in a large unselected IPF population. Methods: We used the Australian IPF Registry to examine the relationship between HRQoL, measured using the St George Respiratory Questionnaire (SGRQ), and demographic features, physiological features, comorbidities and symptoms. Linear regression analysis was performed to identify predictors of baseline HRQoL, linear mixed model analysis to determine the effect of time and forced vital capacity (FVC) on SGRQ and Cox proportional hazards regression to examine the relationship between HRQoL and all-cause mortality. Results: Baseline data from 516 patients were available (347 males; mean (SD) age: 71.3 AE 8.6 years). Univariate analysis showed significant associations between HRQoL and demographic, clinical and physiological features. However, multivariate analysis demonstrated independent associations only between SGRQ and dyspnoea (University of California San Diego Shortness of Breathlessness Questionnaire (UCSD-SOBQ); R 2 = 0.71, P < 0.0001), cough severity (visual analogue scale; R 2 = 0.06, P < 0.0001) and depression (Hospital Anxiety and Depression Scale; R 2 = 0.04, P < 0.0001). Linear mixedeffects modelling of combined baseline and longitudinal data confirmed these associations, as well as for FVC% predicted (P = 0.005). Multivariate Cox proportionateproportional hazards regression analysis demonstrated no association between HRQoL and risk of mortality. Conclusion: Cough, dyspnoea and depression are major symptomatic determinants of HRQoL in IPF. FVC decline is associated with worsening HRQoL.
INTRODUCTION
Patient-reported outcome (PRO) measurements, including measures of health-related quality of life (HRQoL) and symptoms, are increasingly seen as important outcomes in determining the efficacy of anti-fibrotic therapy for idiopathic pulmonary fibrosis (IPF). 1, 2 Recent clinical trials have demonstrated reduction in disease progression as measured by change in forced vital capacity (FVC) % predicted, but no benefit with regards PRO. 3, 4 To better understand how HRQoL might be improved for IPF sufferers, a clear understanding of its underlying contributing factors is needed.
The St George Respiratory Questionnaire (SGRQ), initially designed to study COPD cohorts, has commonly been applied to IPF clinical research, with a number of studies supporting its validity in capturing HRQoL. [5] [6] [7] Typically, abnormality is demonstrated within its activity domains most significantly, with less abnormality seen within impacts and symptom domains, reflecting the reduced frequency of sputum and wheeze in IPF sufferers. 8 Systematic review of other measures of HRQoL has demonstrated profound impairment of quality of life in IPF patients, with physical health domains also being the most severely impacted. 9 Previously, dyspnoea has been shown to have the strongest correlation with quality of life, while physiological measurements have demonstrated only moderate correlation. 9 Such research has been based upon either relatively small single-centre patient populations or highly refined groups such as those within clinical trials. 10, 11 We hypothesized that in a large unselected longitudinal registry, dyspnoea would continue to demonstrate a strong relationship with HRQoL, but other IPF symptoms would also prove to be contributors. We also hypothesized HRQoL would demonstrate an association with disease progression, measured using standard physiological measurements.
METHODS

Study patients
The Australian IPF Registry is a nationwide collaboration, initiated and administered by the Lung Foundation of Australia. The registry's structure, governance and methodology have previously been described. 12 
Measurements
Data collected by the Australian IPF Registry include, at baseline and every 6 months subsequently, HRQoL and symptom measurements. HRQoL is measured using the SGRQ, a 50-item questionnaire scored between 0 and 100, with higher scores reflecting greater limitation. 13 Symptom measurements include breathlessness, measured using the University of California San Diego Shortness of Breathlessness Questionnaire (UCSD-SOBQ), a 24-item questionnaire scored between 0 and 120, with higher scores reflecting greater dyspnoea; anxiety and depression, measured using the Hospital Anxiety and Depression Scale (HADS), a 14-item questionnaire scored between 0 and 21 for anxiety and depression, with a score between 8 and 10 reflecting borderline caseness and scores above 10 reflecting caseness for anxiety and depression; and cough presence and severity, measured between 0 and 100 mm using a visual analogue scale (VAS), with anchors of 'no cough' and 'worst cough imaginable'. 14, 15 At each physician-patient interaction, a questionnaire is completed by the physician that includes data about hospitalization and acute exacerbation. The registry does not stipulate the frequency of physician-patient interactions, nor the nature or number of investigations or interventions carried out on entered subjects. All lung function testing is obtained, with reference values for physiological tests being those of Quanjer et al. for spirometric indices and Gulsvik et al. for diffusion capacity of carbon monoxide (DL CO ). 16, 17 Outcome data, including vital status and transplantation, are collected by state-based coordinators for all patients included within the registry and was up to date at the time of censoring of the data at August 2014.
Statistical analysis
All available data collected at baseline and longitudinally are included in this analysis. Predictors of baseline HRQoL were identified via univariate and multivariate linear regression analyses. Predictors of all-cause mortality were determined using univariate and multivariate Cox proportional hazards regression analyses. Variables with P < 0.10 on univariate analyses or those judged to be clinically important were considered for inclusion in the multivariate models to assess their independent association with HRQoL or all-cause mortality. Multivariate models were constructed using stepwise selection and backward elimination procedures before undergoing a final assessment for clinical and biological plausibility. Linear mixed-effects regression analysis was performed using the PROC MIXED procedure in SAS to determine the association between physiological measures, FVC, symptom scores and HRQoL. All observed data were considered for analysis, with the mixed-effects models assuming noninformative dropout such that the probability of dropout may depend on a participant's previous response but not on current or future responses. Continuous variables were summarized using mean AE SD or median (interquartile range) wherever appropriate. Categorical variables were expressed as counts and proportions. Statistical significance was set at a two-sided P-value of 0.05. Data analysis was performed using SAS software version 9.4 (SAS Institute, Cary, NC, USA).
RESULTS
Demographics
From the commencement of data collection in February 2012 until August 2014, 516 patients had been referred to the registry. Demographic and clinical characteristics are shown in Table 1 . The majority of subjects within the registry were males at 67.3%. The average age of subjects was 71.3 AE 8.6 years and the majority were Caucasian at 95.5%.
Physiology
Baseline physiological data, including derived Gender, Age, Physiology Index (GAP) and Composite Physiologic Index (CPI) scores, are summarized in Table 2 . 18, 19 Mild spirometric impairment and a relatively widely distributed pattern of abnormality were demonstrated with a mean FVC% predicted of 81.0 AE 22.5% (n = 231). Gas transfer was more severely impaired, with a mean value of 46.7 AE 17.4% (n = 204), again displaying a broad range of values. For the 231 subjects with all data available, 37.1% were GAP stage 1, 44.4% were GAP stage 2 and 18.5% were GAP stage 3.
Clinical findings
Quality of life and symptom measurements are displayed in Table 2 . The mean SGRQ total score was 46.6 AE 20.9 (n = 399). Significant impairment was demonstrated in all three domains with the most significant impairment seen within the activity domain (mean score of 61.9 AE 23.9, n = 414). Patients-reported breathlessness yielded a median UCSD-SOBQ score of 38 (n = 279, interquartile range: 17-63). Mood disturbance was frequently reported: 24.7% of subjects had an HADS-A score ≥ 8 (n = 408) and 24.2% had a HADS-D score ≥ 8 (n = 417). 20 Cough was a near ubiquitous feature, 88.5% of subjects reporting its presence, with a median score of 40.3 mm (n = 378, interquartile range: 21, 56).
Predictors of HRQoL
Multiple predictors of HRQoL were apparent upon univariate linear regression analysis, as shown in Table 3 . The strongest independent association with total SGRQ occurred for symptom measures, with dyspnoea demonstrating the strongest association (R 2 = 0.76). Physiological values were less strongly associated with baseline DL CO having the strongest association (R 2 = 0.22). Respiratory hospitalization and death were each associated with an increased SGRQ total score, with a mean score of 15.67 and 15.77 points higher, respectively, than a population in whom those events did not occur.
Multivariate analysis revealed that breathlessness and cough, along with the severity of depression, were the only independent predictors of quality of life (Table 4) . Of those, dyspnoea was the major predictor, accounting for nearly 71% of the variation within the model of total SGRQ score. Cough severity accounted for a further 5.7% of variation, while depression accounted for 3.5% of variation.
Longitudinal data demonstrated progressive clinical and physiological decline. A relative minority of subjects had data available at both baseline and within 100 days of 12 months subsequently, and 38% of those subjects (n = 64) experienced an increase in their SGRQ total score greater than the suggested minimally important clinical difference (MICD) of 7 (median change = 1.33, interquartile range: −6.1, 12.7). 6 Fiftythree percent of subjects with the same data available (n = 51) experienced an increase in their UCSD-SOBQ of the reported MICD of at least 8 with a median increase of 6 (interquartile range" 0, 21). 21 Median increase in cough severity was 3 mm (interquartile range: −9.5, 15). The median relative decline in FVC% predicted at 12 months was 5% (interquartile range: −12.6%, 1.1%).
To account for multiple measurements performed at variable time points, a linear mixed-effects model was used to examine the association between physiological decline and time (Fig. 1) . Progressive physiological decline was confirmed with a significant association seen between time post-baseline and change in FVC% predicted. A 5% absolute decline was observed between baseline and values obtained more than 12 months from baseline (P < 0.001). A similar association was seen for fall in DL CO % predicted, falling by 4.1% between baseline and values obtained >12 months from that time point (P = 0.003).
To explore the link between longitudinal change in physiology and HRQoL, a linear mixed-effects model was used to examine the relationship between FVC% predicted and each SGRQ domain and total scores collected at baseline and longitudinally (Table 5) . At least one follow-up set of data for HRQoL was available for 207 subjects within the symptoms domain of the SGRQ, 210 subjects within the activity domain, 206 subjects within the impacts domain and 202 subjects for the total SGRQ score. One hundred and twenty-five subjects had repeat lung function testing data available for analysis. A significant association was demonstrated for each in an unadjusted model. For every 1% decline in FVC% predicted, the SGRQ increased by 0.30 (P < 0.0001). The strongest association was seen within the activity domain which increased on average by a value of 0.34 for every 1% decline in FVC% predicted. This association remained significant for all but the SGRQ symptom domain when the model was adjusted for dyspnoea, cough and depression, the values found to predict for baseline HRQoL (SGRQ total score, P = 0.005).
To examine the relationship between SGRQ and survival, Cox proportional hazards regression analysis was performed. Univariate analysis demonstrated a significant association between all-cause mortality and baseline values for SGRQ total score (P < 0.0001), DL CO % predicted (P < 0.0001), GAP index (P < 0.0001), CPI (P < 0.0001), FVC% predicted (P = 0.003) and age (P = 0.034). Gender was not found to be significantly associated (P = 0.159). Upon multivariate analysis, only baseline gas transfer (P = 0.026) and GAP index (P = 0.002) were significant predictors for all-cause mortality, and no significant association with baseline SGRQ total score was demonstrated (P = 0.145).
DISCUSSION
This study clearly identifies three major patientreported contributors to HRQoL in IPF, as measured by the SGRQ: dyspnoea, cough and depression. Of those, dyspnoea is the most significant contributor, explaining 71% of the variation seen in total SGRQ upon multivariate analysis. Our study is the first to use a VAS to explore the importance of cough with respect to quality of life and demonstrates that cough is an important cocontributor to quality of life. Mood disturbance in the form of depression is the third small significant contributor to quality of life; the direction of that interaction is unclear. These findings suggest that therapeutic strategies to improve quality of life should target symptom control.
Using a mixed-effects model analysis combining baseline and longitudinal data to explore the association between total SGRQ and FVC% predicted, we demonstrate a significant association in an unadjusted model, which remained significant after adjusting for symptoms. This linkage between worsening physiology and symptoms and declining HRQoL builds on the longitudinal construct validity for the SGRQ in measuring IPF HRQoL. While a link between HRQoL and physiological decline has been suggested in a single-centre study of 45 patients, recent trials of anti-fibrotic therapy have not demonstrated preservation of quality of life and symptom scores despite slowing the decline in FVC. 5 The INPULSIS studies of nintedanib in IPF measured HRQoL using the SGRQ, demonstrating a nonsignificant trend for its preservation among those receiving active therapy. 4 The ASCEND studies of pirfenidone's inability to demonstrate improvement in dyspnoea among those on active therapy suggest that no preservation of quality of life would be seen either, given the strong linkage between dyspnoea and quality of life seen in ours and other studies. 3, 7 Our findings suggest that were studies of anti-fibrotic therapy powered in a manner where changes in HRQoL could be more accurately recognized, a significant benefit with regards this PRO might be seen. So far, IPF clinical studies have used the SGRQ; potentially were IPFspecific HRQoL PROs used, such as the SGRQ-I ATAQ-I or K-BILD, this effect may be more apparent, particularly if studies were performed over longer durations and in milder cohorts prior to profound decline had occurred. [22] [23] [24] Our study's findings should be viewed in the context of a number of limitations. First, we do not mandate multidisciplinary discussion for inclusion in the Australian IPF Registry and therefore, our cohort potentially includes those suffering other forms of fibrotic lung disease. However, it has recently been shown that multidisciplinary discussion provides little additional benefit with regards to diagnostic agreement for IPF diagnosis, as opposed to that made by individual clinicians. 25 Second, many subjects recruited to the registry could not be included in the complete analysis due to data being not available at the time of data censoring. Nevertheless, our cohort of several hundred patients with complete data is sufficiently large to provide a signal with high statistical confidence for many of the findings of this study.
The SGRQ was designed for patients with COPD and its applicability to IPF can therefore be questioned. Its utility in IPF has been most extensively examined by Swigris et al., who, in a review of 30 studies, conclude that despite this questionable face validity, the internal consistency of the 'activity' and 'impacts' domains and total score from the SGRQ was excellent, and that the SGRQ demonstrates moderate to strong correlation with other PROs and physiological variables, and possesses discriminatory ability for severity of disease. 26 Our study's finding of numerous univariate associations between features of disease severity and reduced HRQoL within cross-sectional baseline data, in addition to the multivariate analysis of baseline and longitudinal data described above, supports that conclusion. While the correlation we have demonstrated between the cough VAS and quality of life goes some of the way to providing validation, further validation to examine its reliability, inter-relatedness and longitudinal behaviour is required. Finally, because anti-fibrotic therapy has been available for only a limited period and was not approved by the Australian Therapeutic Goods Administration at the time of data collection, we were unable to analyse the effect of anti-fibrotic therapy upon quality of life. In summary, this study highlights the importance of dyspnoea, cough and depression as major cocontributors to quality of life among sufferers of IPF and their importance as therapeutic targets if quality of life is to be improved. It also confirms the association between decline in FVC% predicted, the major physiological endpoint of clinical trials in anti-fibrotic therapy, and falling quality of life, suggesting that the signal of benefit seen within one of the recent anti-fibrotic therapies was genuine. Finally, it significantly strengthens arguments for the plausible use of quality of life measures as primary endpoints in future studies of anti-fibrotic therapy.
